149 related articles for article (PubMed ID: 34599724)
1. How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate cancer?
Urabe F; Kimura T; Sasaki H; Tashiro K; Iwatani K; Yasue K; Aoki M; Sato S; Takahashi H; Miki K; Egawa S
Int J Clin Oncol; 2022 Jan; 27(1):184-193. PubMed ID: 34599724
[TBL] [Abstract][Full Text] [Related]
2. Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy.
Niwa N; Matsumoto K; Nishiyama T; Yagi Y; Ozu C; Nakamura K; Saito S; Oya M
Brachytherapy; 2018; 17(6):899-905. PubMed ID: 30245170
[TBL] [Abstract][Full Text] [Related]
3. Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrence.
Nakazono M; Urabe F; Iwatani K; Imai Y; Tashiro K; Honda M; Koike Y; Shimomura T; Sato S; Takahashi H; Miki K; Aoki M; Kimura T
Int J Urol; 2023 Dec; 30(12):1147-1154. PubMed ID: 37650359
[TBL] [Abstract][Full Text] [Related]
4. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
[TBL] [Abstract][Full Text] [Related]
6. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244
[TBL] [Abstract][Full Text] [Related]
7. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
8. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Biochemical Control of a Prospective Cohort of Prostate Cancer Patients Treated With Interstitial Brachytherapy Versus Radical Prostatectomy.
Sanmamed N; Locke G; Crook J; Liu A; Raman S; Glicksman R; Chung P; Berlin A; Fleshner N; Helou J
Clin Oncol (R Coll Radiol); 2023 Apr; 35(4):262-268. PubMed ID: 36737311
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
[TBL] [Abstract][Full Text] [Related]
11. Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer.
Luo Y; Li M; Qi H; Zhao J; Han Y; Lin Y; Hou Z; Jiang Y
World J Surg Oncol; 2018 Jun; 16(1):107. PubMed ID: 29890979
[TBL] [Abstract][Full Text] [Related]
12. Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
Tanaka N; Asakawa I; Nakai Y; Miyake M; Anai S; Fujii T; Hasegawa M; Konishi N; Fujimoto K
BMC Cancer; 2017 Aug; 17(1):573. PubMed ID: 28841855
[TBL] [Abstract][Full Text] [Related]
13. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis.
Pickles T; Keyes M; Morris WJ
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):43-9. PubMed ID: 19570619
[TBL] [Abstract][Full Text] [Related]
14. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
15. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of radical prostatectomy versus low-dose-rate brachytherapy in patients with intermediate-risk prostate cancer: Propensity score matched comparison.
Urabe F; Miki K; Kimura T; Sasaki H; Tashiro K; Iwatani K; Matsukawa A; Aikawa K; Tsusumi Y; Morikawa M; Minato K; Sato S; Takahashi H; Aoki M; Egawa S
Prostate; 2023 Feb; 83(2):135-141. PubMed ID: 36176043
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of PSA bounce after definitive radiotherapy revisited.
Urabe F; Kimura T; Sasaki H; Tashiro K; Iwatani K; Aoki M; Sato S; Takahashi H; Miki K; Egawa S
Int J Clin Oncol; 2022 Feb; 27(2):411-417. PubMed ID: 34677737
[TBL] [Abstract][Full Text] [Related]
18. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
19.
Kindts I; Stellamans K; Billiet I; Pottel H; Lambrecht A
Strahlenther Onkol; 2017 Sep; 193(9):707-713. PubMed ID: 28488030
[TBL] [Abstract][Full Text] [Related]
20. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Stock RG; Stone NN
Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
